Explore our latest projects!
Thanks to our experience, we are able to provide high quality technological solutions for the pharmaceutical industry. With the support of other companies and organisations, we continue to work committed to continuous innovation.
Grifols Engineering builds a plasma fractionation plant in Egypt
Grifols and the Egyptian Government, through the National Service Projects Organization, have a strategic agreement to boost self-sufficiency in plasma-derived medicines in Egypt and the broader region.
Lee más sobre el proyecto
Grifols y el Gobierno de Egipto, a través de la National Service Projects Organization (NSPO), llegaron a un acuerdo estratégico para el desarrollo del mercado de medicamentos plasmáticos e impulsar su autosuficiencia a nivel nacional. Esta operación permitirá fortalecer el sistema sanitario egipcio.
Ambas partes combinando su experiencia industrial y esfuerzos financieros para diseñar, construir y poner en marcha 20 centros de donación de plasma en Egipto con una capacidad inicial para la obtención de 600.000 litros de plasma al año, así como instalaciones productivas que incluyen:
- Una planta de fraccionamiento (con capacidad para fraccionar hasta 1 millón de litros de plasma al año, ampliable a 2 millones)
- Una planta de purificación y dosificación
- Un almacén
- Un laboratorio de análisis
Grifols Engineering es la encargada de gestionar la construcción y la puesta en marcha de las instalaciones productivas en una parcela de 105.000 m², en el área de Nueva Capital Administrativa.
Se espera que los centros de donación plasma y las instalaciones estén en funcionamiento a finales de 2025.
Plasma fractionation plant
Grifols Engineering produces modular test centers for Liberia
Grifols Engineering, together with the Probitas Foundation , has installed new modular centers in Liberia to centralize the testing of plasma samples from donors who have survived Ebola.
Read more about the project
Grifols Engineering, together with the Probitas Foundation , has installed new modular centers in Liberia to produce anti-Ebola immunoglobulins.
The purpose of these modules is to centralize the testing of samples from donors who have recovered from Ebola, thus improving the process and the gathering of results. The samples obtained are tested using the PCR technique (Polymerase Chain Reaction), which is used to amplify DNA sequences.
The new centers are organized into two independent areas: the PCR tests for detecting Ebola and Lassa fever are carried out in the first, and HIV and hepatitis B and C in the second.
Grifols Engineering implemented 100% of the design and the construction of the new modules, resulting in a significant improvement in the thermal insulation features and climate elements. The modules also incorporate solar panels and other elements to guarantee the sustainability of the facility.
The new modules come eight years after Grifols deliver the first modular plasma donor center in Monrovia to collect plasma form donors who had survived Ebola and as part of the company’s commitment to combat the disease.
Since Grifols reached an agreement with the Government of the Republic of Liberia, Grifols Engineering has continued strengthening the project's key elements, such as improving the design of the modular centers, always adhering to the highest standards of quality.
New modular centers
¿How can we help you?
For general, commercial, and technical inquiries, please contact the Grifols Engineering team directly.